Nalidixic acid
From Wikipedia, the free encyclopedia
Nalidixic acid
|
|
Systematic (IUPAC) name | |
1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid | |
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C12H12N2O3 |
Mol. mass | 232.235 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 90% |
Metabolism | Partially Hepatic |
Half life | 6-7 hours, significantly longer in renal impairment |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
B U.S. |
Legal status | |
Routes | Oral |
Nalidixic acid is the basis for quinolone antibiotics.
It acts bacteriostatically (that is, it inhibits growth and reproduction) or bactericidally (it kills them) on both Gram positive and Gram negative bacteria, depending on the concentration.
It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, shigella, Enterobacter and Klebsiella.
[edit] External links
[edit] See also
|
|
---|---|
Fluoroquinolones | Ciprofloxacin, Enoxacin, Fleroxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Levofloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Ofloxacin, Pefloxacin, Prulifloxacin, Rufloxacin, Sparfloxacin, Temafloxacin, Trovafloxacin, Sitafloxacin |
Other quinolones | Cinoxacin, Flumequine, Nalidixic acid, Oxolinic acid, Pipemidic acid, Piromidic acid, Rosoxacin |